Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial
E Kaplovitch, JW Eikelboom, L Dyal, V Aboyans… - JAMA …, 2021 - jamanetwork.com
Importance Patients with symptomatic lower extremity peripheral artery disease (LE-PAD)
experience an increased risk of major vascular events. There is limited information on what …
experience an increased risk of major vascular events. There is limited information on what …
[PDF][PDF] Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease A Subanalysis of the COMPASS Randomized Clinical Trial
E Kaplovitch, JW Eikelboom, L Dyal, V Aboyans… - JAMA, 2021 - amedeolucente.it
OBJECTIVE To quantify the risk of major vascular events and investigate the response to
treatment with low-dose rivaroxaban and aspirin among patients with symptomatic LE-PAD …
treatment with low-dose rivaroxaban and aspirin among patients with symptomatic LE-PAD …
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease
E Kaplovitch, J Eikelboom, L Dyal, V Aboyans… - JAMA Cardiology, 2020 - hal.science
Importance: Patients with symptomatic lower extremity peripheral artery disease (LE-PAD)
experience an increased risk of major vascular events. There is limited information on what …
experience an increased risk of major vascular events. There is limited information on what …
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial
E Kaplovitch, JW Eikelboom, L Dyal, V Aboyans… - 2020 - hero.epa.gov
Importance: Patients with symptomatic lower extremity peripheral artery disease (LE-PAD)
experience an increased risk of major vascular events. There is limited information on what …
experience an increased risk of major vascular events. There is limited information on what …
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial
E Kaplovitch, JW Eikelboom, L Dyal, V Aboyans… - 2021 - pubmed.ncbi.nlm.nih.gov
Importance Patients with symptomatic lower extremity peripheral artery disease (LE-PAD)
experience an increased risk of major vascular events. There is limited information on what …
experience an increased risk of major vascular events. There is limited information on what …
[PDF][PDF] Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease A Subanalysis of the COMPASS Randomized Clinical Trial
E Kaplovitch, JW Eikelboom, L Dyal, V Aboyans… - JAMA, 2021 - amedeolucente.it
OBJECTIVE To quantify the risk of major vascular events and investigate the response to
treatment with low-dose rivaroxaban and aspirin among patients with symptomatic LE-PAD …
treatment with low-dose rivaroxaban and aspirin among patients with symptomatic LE-PAD …
[PDF][PDF] Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease A Subanalysis of the COMPASS Randomized Clinical Trial
E Kaplovitch, JW Eikelboom, L Dyal, V Aboyans… - 2020 - lirias.kuleuven.be
OBJECTIVE To quantify the risk of major vascular events and investigate the response to
treatment with low-dose rivaroxaban and aspirin among patients with symptomatic LE-PAD …
treatment with low-dose rivaroxaban and aspirin among patients with symptomatic LE-PAD …
[HTML][HTML] Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial
E Kaplovitch, JW Eikelboom, L Dyal, V Aboyans… - JAMA …, 2021 - ncbi.nlm.nih.gov
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery
Disease - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
Disease - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
E Kaplovitch, JW Eikelboom, L Dyal, V Aboyans… - JAMA …, 2021 - europepmc.org
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery
Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. - Abstract - Europe PMC …
Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. - Abstract - Europe PMC …
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease
E Kaplovitch, J Eikelboom, L Dyal, V Aboyans… - JAMA …, 2020 - unilim.hal.science
Importance: Patients with symptomatic lower extremity peripheral artery disease (LE-PAD)
experience an increased risk of major vascular events. There is limited information on what …
experience an increased risk of major vascular events. There is limited information on what …